Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

NCT06084481 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06084481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06084481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
November 9, 2023
Completion date
September 30, 2027
Enrollment
325 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancers, esophageal squamous cell carcinoma, head and neck squamous-cell carcinoma, hepatocellular carcinoma, hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer, pancreatic ductal adenocarcinoma, platinum resistant high grade epithelial ovarian cancer, triple negative breast cancer